Richard Haggerty

Richard Haggerty


Latest posts

Cardiff University Research Consultants Successfully Help Wales-Based Researchers To Bring In £1 Million Of New Funding

Posted on 5 April 2017 by Richard Haggerty

Experts in the Research Design and Conduct Service (RDCS) South East Wales, based in the Centre for Trials Research at Cardiff University, worked with 115 teams across Wales to develop novel research ideas in 2016. The RDCS supported 16 teams to put in well-designed submissions to a variety of funding bodies through the year. Senior
Read more


INDUCE Study Wins ‘Jewel In The Crown’ Presentation At The College Of Podiatry Annual Conference And Exhibition In Glasgow

Posted on 14 December 2016 by Richard Haggerty

I presented at The College of Podiatry annual conference and exhibition in Glasgow on the 17th Nov 2016. The INDUCE study was selected as the Jewel in the Crown presentation from around 50 entries of short papers and poster presentations. Following a prize giving I was able to present, on the main stage, an overview of
Read more


Gwenllian Moody presenting on the challenge of collecting focus group data in partnership with geographically dispersed and time-pressed professionals.

South West Society for Academic Primary Care 2016 Annual Meeting

Posted on 23 March 2016 by Richard Haggerty

The South East Wales Trials Unit (SEWTU) based in the Centre for Trials Research at Cardiff University recently co-hosted the South West Society for Academic Primary Care 2016 Annual Meeting along with colleagues in the Division of Population Medicine. The event brought together over 160 experts and researchers in the field of primary care to present
Read more


FRAGMATIC: Results of the Largest UK Trial of Lung Cancer Patients with Low Molecular Weight Heparin

Posted on 9 February 2016 by Richard Haggerty

The results of the Fragmatic trial were recently published in the Journal of Clinical Oncology. The trial was funded by Cancer Research UK with support from Pfizer to answer this question: ‘Should all newly diagnosed people with lung cancer be offered daily injections of a drug called dalteparin for six months to improve survival and
Read more